What is Clarapath?
Founded in 2014 and headquartered in Hawthorne, New York, Clarapath is positioned at the intersection of medical robotics and digital pathology. The company specializes in developing sophisticated hardware and software solutions designed to automate the labor-intensive processes inherent in pathology laboratories. By replacing manual, error-prone workflows with high-precision robotic systems, Clarapath aims to enhance diagnostic accuracy, reduce turnaround times, and improve overall laboratory efficiency. Their market position is bolstered by a commitment to integrating cutting-edge technology into the clinical environment, effectively bridging the gap between traditional pathology practices and the future of automated, data-driven healthcare delivery.
How much funding has Clarapath raised?
Clarapath has raised a total of $68M across 2 funding rounds:
Series B
$32M
Series B
$36M
Series B (2021): $32M with participation from East Post Road Ventures, Epiphron Capital Group, and P5 Health Ventures
Series B (2024): $36M led by CU Healthcare Innovation Fund and Mayo Clinic
Key Investors in Clarapath
CU Healthcare Innovation Fund
A strategic venture capital firm affiliated with the University of Colorado Anschutz Medical Campus that leverages an extensive research ecosystem to validate and scale healthcare solutions.
Mayo Clinic
A globally recognized nonprofit healthcare organization that integrates clinical practice, research, and education to drive medical advancement and innovation.
East Post Road Ventures
A venture firm specializing in early-stage healthcare and medical device investments, focused on commercializing innovative concepts that improve patient care delivery.
What's next for Clarapath?
The recent infusion of capital is expected to catalyze the next phase of Clarapath's growth, likely focusing on the commercial scaling of its robotic platforms and the expansion of its footprint within major healthcare systems. As the company transitions from development to widespread clinical adoption, strategic priorities will likely include strengthening its intellectual property portfolio, enhancing its software-as-a-service (SaaS) capabilities for pathology data management, and deepening partnerships with leading medical institutions. By leveraging the expertise of its strategic investors, Clarapath is well-positioned to set a new standard for efficiency and precision in the global pathology market, ultimately driving better patient outcomes through technological innovation.
See full Clarapath company page
